Company Arcturus Therapeutics Ltd Nasdaq
Equities
IL0011280240
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Nucleic Acid-focused Technology
100.0
%
| 206 | 100.0 % | 167 | 100.0 % | -19.03% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 206 | 100.0 % | 167 | 100.0 % | -19.03% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Joseph Payne
CEO | Chief Executive Officer | 52 | 28/02/13 |
Andrew Sassine
DFI | Director of Finance/CFO | 59 | 31/12/18 |
Chief Operating Officer | 45 | 31/12/12 | |
Chief Tech/Sci/R&D Officer | 68 | 28/02/23 | |
Neda Safarzadeh
IRC | Investor Relations Contact | - | - |
Lance Kurata
LAW | General Counsel | 54 | 09/08/20 |
Kevin T. Skol
PRN | Corporate Officer/Principal | - | 31/12/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Edward W. Holmes
BRD | Director/Board Member | 83 | 31/08/19 |
James F. Barlow
BRD | Director/Board Member | 65 | 26/05/18 |
Peter Farrell
CHM | Chairman | 81 | 26/05/18 |
Andrew Sassine
DFI | Director of Finance/CFO | 59 | 31/12/18 |
Magda Marquet
BRD | Director/Board Member | 65 | 26/05/18 |
Jing Marantz
BRD | Director/Board Member | 59 | 06/12/21 |
Joseph Payne
CEO | Chief Executive Officer | 52 | 28/02/13 |
John Markels
BRD | Director/Board Member | 58 | 07/12/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 26,931,826 | 24,577,248 ( 91.26 %) | 0 | 91.26 % |
Company contact information
Arcturus Therapeutics Holdings, Inc.
10628 Science Center Drive Suite 250
92121, San Diego
+
http://www.arcturusrx.comSector
1st Jan change | Capi. | |
---|---|---|
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+49.84% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
-1.62% | 11.98B |